Should I buy or sell Guardant Health stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GH shares. View GH analyst ratings or view top-rated stocks .

What is Guardant Health's stock price target for 2024?

12 Wall Street analysts have issued 1-year price targets for Guardant Health's shares. Their GH share price targets range from $27.00 to $55.00. On average, they expect the company's stock price to reach $40.40 in the next year. This suggests a possible upside of 151.4% from the stock's current price. View analysts price targets for GH or view top-rated stocks among Wall Street analysts .

How have GH shares performed in 2024?

Guardant Health's stock was trading at $27.05 at the beginning of the year. Since then, GH stock has decreased by 40.6% and is now trading at $16.07. View the best growth stocks for 2024 here .

When is Guardant Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GH earnings forecast .

How can I listen to Guardant Health's earnings call?

Guardant Health will be holding an earnings conference call on Thursday, May 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) released its quarterly earnings results on Thursday, February, 22nd. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($0.93) by $0.65. The company earned $155.05 million during the quarter, compared to analyst estimates of $151.71 million. Guardant Health had a negative trailing twelve-month return on equity of 301.94% and a negative net margin of 85.02%.

What ETFs hold Guardant Health's stock?

ETFs with the largest weight of Guardant Health (NASDAQ:GH) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS) , ROBO Global Healthcare Technology and Innovation ETF (HTEC) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) , iShares U.S. Healthcare Providers ETF (IHF) , ARK Genomic Revolution ETF (ARKG) and Franklin Genomic Advancements ETF (HELX) . Invesco Nasdaq Biotechnology ETF (IBBQ) .

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $655.0 million-$670.0 million, compared to the consensus revenue estimate of $669.4 million.

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com . Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA) , Trade Desk (TTD) , Block (SQ) , Alibaba Group (BABA) , PayPal (PYPL) , Shopify (SHOP) , Okta (OKTA) , Alteryx (AYX) , Roku (ROKU) and Twilio (TWLO) .

When did Guardant Health IPO?

Guardant Health (GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.26%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Amelia Merrill , Amirali Talasaz , Helmy Eltoukhy , Ian T Clark , Kumud Kalia , Meghan V Joyce , Samir Kaul , Stanley J Meresman and Stanley J Meresman . View institutional ownership trends .

How do I buy shares of Guardant Health?

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GH

Guardant Health (GH) Stock Price, News & Analysis

→ The #1 Opportunity of the decade? (From Behind the Markets) (Ad)

Free GH Stock Alerts

$16.07

-0.60 (-3.60%)

(As of 04:00 PM ET)

Compare

Today's Range: $15.81
▼
$16.79
50-Day Range: $16.16
▼
$23.23
52-Week Range: $15.81
▼
$41.06

Volume: 1.85 million shs
Average Volume: 1.90 million shs
Market Capitalization: $1.96 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $40.40

Get Guardant Health alerts:

Guardant Health MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 151.4% Upside
$40.40 Price Target
Short Interest: Bearish
6.28% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.51
Upright™ Environmental Score
News Sentiment: -0.34
Based on 10 Articles This Week
Insider Trading: Acquiring Shares
$38,972 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($3.49) to ($3.23) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.49 out of 5 stars

Medical Sector

91st out of 911 stocks

Medical Laboratories Industry

3rd out of 20 stocks

4.4

Analyst's Opinion

Consensus Rating
Guardant Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Guardant Health has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
6.28% of the outstanding shares of Guardant Health have been sold short.
Short Interest Ratio / Days to Cover
Guardant Health has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Guardant Health has recently decreased by 1.55%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Guardant Health does not currently pay a dividend.
Dividend Growth
Guardant Health does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Guardant Health has received a 71.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Genomics analysis tools" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Guardant Health is -0.51.

1.5

News and Social Media Coverage

News Sentiment
Guardant Health has a news sentiment score of -0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Guardant Health this week, compared to 4 articles on an average week.
Search Interest
21 people have searched for GH on MarketBeat in the last 30 days. This is an increase of 62% compared to the previous 30 days.
MarketBeat Follows
Only 12 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Guardant Health insiders have bought 1,945.77% more of their company's stock than they have sold. Specifically, they have bought $38,972.00 in company stock and sold $1,905.00 in company stock.
Percentage Held by Insiders
Only 6.20% of the stock of Guardant Health is held by insiders.
Percentage Held by Institutions
92.60% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Guardant Health are expected to grow in the coming year, from ($3.49) to ($3.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Guardant Health is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Guardant Health is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Guardant Health has a P/B Ratio of 11.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Guardant Health Stock (NASDAQ:GH)

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

GH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GH Stock News Headlines

March 20, 2024 | insidertrades.com

Guardant Health, Inc. (NASDAQ:GH) Insider Purchases $38,972.34 in Stock

April 18, 2024 | businesswire.com

Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 17, 2024 | msn.com

Mass. General Hospital granted unanimous approval to add dozens of inpatient beds

April 17, 2024 | msn.com

Romance Is In The Air On General Hospital

April 17, 2024 | msn.com

General Hospital Spoilers: Will Cyrus Decide Sonny's Prison Fate?

April 17, 2024 | americanbankingnews.com

Guardant Health (NASDAQ:GH) Reaches New 1-Year Low After Analyst Downgrade

April 16, 2024 | americanbankingnews.com

Guardant Health (NASDAQ:GH) Price Target Cut to $28.00 by Analysts at The Goldman Sachs Group

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 12, 2024 | yahoo.com

General Hospital Video Preview: Decisions, Disrespect, and Deception

April 12, 2024 | msn.com

What The Heck Just Happened On General Hospital?

April 10, 2024 | americanbankingnews.com

Guardant Health, Inc. (NASDAQ:GH) Receives Average Recommendation of "Moderate Buy" from Analysts

April 4, 2024 | forbes.com

Guardant Health

April 1, 2024 | investorplace.com

Better Than ChatGPT? New Super AI Bot Says Buy These 3 Stocks.

March 30, 2024 | yahoo.com

General Hospital Comings and Goings: Missing Doc Back, New Castings

March 17, 2024 | finance.yahoo.com

GH Apr 2024 55.000 put

March 16, 2024 | finance.yahoo.com

GH Dec 2025 7.500 put

March 16, 2024 | finance.yahoo.com

GH Jul 2024 10.000 put

March 15, 2024 | msn.com

Cell-Free DNA Test Has 83.1 Percent Sensitivity for Detection of CRC

March 15, 2024 | msn.com

Cathie Wood Darling Exact Sciences, And Rival Guardant Health, Dip On Colon Cancer Updates

March 14, 2024 | ca.news.yahoo.com

Alcohol recovery room at University of Guelph helps ease ER pressure, hospital says

March 13, 2024 | businesswire.com

Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine

March 6, 2024 | businesswire.com

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 6, 2024 | businesswire.com

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 1, 2024 | businesswire.com

New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap

February 26, 2024 | markets.businessinsider.com

Scotiabank Keeps Their Buy Rating on Guardant Health (GH)

February 26, 2024 | markets.businessinsider.com

Buy Rating for Guardant Health Amid Strong Market Position and Promising Future Prospects

See More Headlines

Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/19/2024
Next Earnings (Confirmed): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:GH
CUSIP: N/A
CIK: 1576280
Web: www.guardanthealth.com
Phone: (855) 698-8887
Fax: 888-974-4258
Employees: 1,779
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $40.40
High Stock Price Target: $55.00
Low Stock Price Target: $27.00
Potential Upside/Downside: +151.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-479,450,000.00
Net Margins: -85.02%
Pretax Margin: -84.89%
Return on Equity: -301.94%
Return on Assets: -27.65%

Debt

Debt-to-Equity Ratio: 7.18
Current Ratio: 6.54
Quick Ratio: 6.24

Sales & Book Value

Annual Sales: $563.95 million
Price / Sales: 3.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.34 per share
Price / Book: 11.97

Miscellaneous

Outstanding Shares: 121,710,000
Free Float: 114,167,000
Market Cap: $1.95 billion
Optionable: Not Optionable
Beta: 0.87

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Dr. Helmy Eltoukhy Ph.D. (Age 44)
Co-Founder, Co-CEO & Chairman
Comp: $11.63k
Dr. AmirAli Talasaz Ph.D. (Age 44)
Co-CEO & Director
Comp: $11.18k
Mr. Michael Bell (Age 55)
Chief Financial Officer
Comp: $630.99k
Mr. John G. Saia (Age 51)
Chief Legal Officer & Corporate Secretary
Comp: $627.18k
Dr. Craig Eagle M.D. (Age 57)
Chief Medical Officer
Comp: $649.13k
Mr. Christopher Freeman (Age 50)
Chief Commercial Officer
Comp: $630.39k
Ms. Darya Chudova
Chief Technology Officer
Mr. Kumud Kalia (Age 58)
Chief Information Officer
Ms. Jennifer Higgins
Vice President of Public Affairs
Ms. Terilyn Juarez Monroe (Age 57)
Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GH Stock Analysis - Frequently Asked Questions

Should I buy or sell Guardant Health stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GH shares.
View GH analyst ratings or view top-rated stocks.
What is Guardant Health's stock price target for 2024?: 12 Wall Street analysts have issued 1-year price targets for Guardant Health's shares. Their GH share price targets range from $27.00 to $55.00. On average, they expect the company's stock price to reach $40.40 in the next year. This suggests a possible upside of 151.4% from the stock's current price.
View analysts price targets for GH or view top-rated stocks among Wall Street analysts.
How have GH shares performed in 2024?: Guardant Health's stock was trading at $27.05 at the beginning of the year. Since then, GH stock has decreased by 40.6% and is now trading at $16.07.
View the best growth stocks for 2024 here.
When is Guardant Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GH earnings forecast.
How can I listen to Guardant Health's earnings call?: Guardant Health will be holding an earnings conference call on Thursday, May 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Guardant Health's earnings last quarter?: Guardant Health, Inc. (NASDAQ:GH) released its quarterly earnings results on Thursday, February, 22nd. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($0.93) by $0.65. The company earned $155.05 million during the quarter, compared to analyst estimates of $151.71 million. Guardant Health had a negative trailing twelve-month return on equity of 301.94% and a negative net margin of 85.02%.
What ETFs hold Guardant Health's stock?: ETFs with the largest weight of Guardant Health (NASDAQ:GH) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), iShares U.S. Healthcare Providers ETF (IHF), ARK Genomic Revolution ETF (ARKG) and Franklin Genomic Advancements ETF (HELX).Invesco Nasdaq Biotechnology ETF (IBBQ).

What guidance has Guardant Health issued on next quarter's earnings?: Guardant Health issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $655.0 million-$670.0 million, compared to the consensus revenue estimate of $669.4 million.
What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?: 52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Guardant Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).
When did Guardant Health IPO?: Guardant Health (GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.
Who are Guardant Health's major shareholders?: Guardant Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.26%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Meghan V Joyce, Samir Kaul, Stanley J Meresman and Stanley J Meresman.
View institutional ownership trends.
How do I buy shares of Guardant Health?: Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Guardant Health (GH) Stock Price, News & Analysis

Guardant Health MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Guardant Health Stock (NASDAQ:GH)

GH Stock Price History

GH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™